Aditxt, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
ADTX$0.00-8.6%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended | Year Ended | |
|---|---|---|
| December 31, 2025 | December 31, 2024 | |
| REVENUE | ||
| Sales | $3,195 | $133,985 |
| Cost of goods sold | 2,927 | 627,474 |
| Gross profit (loss) | 268 | (493,489) |
| OPERATING EXPENSES | ||
| General and administrative expenses $0 and $33,071 in stock-based compensation, respectively | 15,974,863 | 16,286,216 |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | 3,194,133 | 10,886,130 |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | 401,996 | 197,863 |
| Total operating expenses | 19,570,992 | 27,370,209 |
| NET LOSS FROM OPERATIONS | (19,570,724) | (27,863,698) |
| OTHER INCOME (EXPENSE) | ||
| Interest expense | (681,156) | (4,188,725) |
| Interest income | 200,179 | 1,454 |
| Amortization of debt discount | (1,706,697) | (3,174,920) |
| Gain (loss) on note exchange agreement | - | (208,670) |
| Change in fair value of derivative liability | 14,515 | 414,501 |
| Change in fair value of Evofem warrants | 2,806,983 | - |
| Impairment of Evofem F-1 Preferred Stock | (23,766,209) | - |
| Bargain purchase gain from purchase of Evofem convertible notes | 328,071 | - |
| Impairment of fixed assets | (412,005) | - |
| Total other expense | (23,216,319) | (7,156,360) |
| Net loss before income taxes | (42,787,043) | (35,020,058) |
| Income tax provision | - | - |
| NET LOSS | $(42,787,043) | $(35,020,058) |
| Deemed Dividends | (1,387,250) | (5,907,011) |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | (1,072,842) | (573,572) |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | $(43,101,451) | $(40,353,497) |
| Net loss per share, basic and diluted | $(1,153.83) | $(22,147,415.22) |
| Weighted average number of shares outstanding during the period, basic and diluted | 37,355 | 2 |
| COMPREHENSIVE LOSS: | ||
| Net Loss | $(42,787,043) | $(35,020,058) |
| Other Comprehensive Loss: | ||
| Change in valuation of Evofem note | 1,254,170 | - |
| TOTAL COMPREHENSIVE LOSS | $(41,532,873) | $(35,020,058) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.